MILAN — Treatment of rheumatoid arthritis (RA) with tumor necrosis factor inhibitors (TNFi) does not appear to demonstrate a consistent and significant risk for demyelinating disease, according to a ...
Demyelination – a term that might sound like scientific jargon but has real-world implications for many. Demyelination occurs when the protective covering of nerve fibers in the brain, spinal cord, ...
The SC formulation of efgartigimod alfa plus hyaluronidase-qvfc is currently marketed under the trade name Vyvgart Hytrulo and is approved for the treatment of generalized myasthenia gravis. The Food ...
Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...
"The pathologic mechanisms leading to moderate enlargement and marked enlargement might be different, thus making different responses to steroids and IVIG. More work should be done to explore the ...
Please provide your email address to receive an email when new articles are posted on . Hyqvia is an immune globulin infusion (human) 10% solution. It was previously approved by the EC for primary ...
(RTTNews) - Takeda (TAK) said that the European Commission approved Hyqvia as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy or CIDP after ...
- Data Show that HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Reduced Relapse Rate Versus Placebo in CIDP Patients When Used as a Maintenance Therapy - Company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback